ATAI Life Sciences/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Ticker
$ATAI
Sector
Primary listing
Employees
54
Headquarters
Website
ATAI Metrics
BasicAdvanced
$986M
-
-$0.69
1.55
-
Price and volume
Market cap
$986M
Beta
1.55
52-week high
$5.34
52-week low
$1.03
Average daily volume
5.7M
Financial strength
Current ratio
4.019
Quick ratio
3.807
Long term debt to equity
3.557
Total debt to equity
8.14
Interest coverage (TTM)
-32.97%
Profitability
EBITDA (TTM)
-94.849
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,171.24%
Operating margin (TTM)
-4,140.32%
Effective tax rate (TTM)
0.58%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-29.51%
Return on equity (TTM)
-76.50%
Valuation
Price to revenue (TTM)
345.813
Price to book
6.79
Price to tangible book (TTM)
6.96
Price to free cash flow (TTM)
-10.396
Free cash flow yield (TTM)
-9.62%
Free cash flow per share (TTM)
-0.442
Growth
Revenue change (TTM)
510.85%
Earnings per share change (TTM)
90.44%
3-year revenue growth (CAGR)
51.35%
3-year earnings per share growth (CAGR)
-18.51%
What the Analysts think about ATAI
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
Bulls say / Bears say
BPL-003 met its primary and all key secondary endpoints in the Phase 2b trial, showing rapid, robust, and durable antidepressant effects that last up to eight weeks from a single dose without serious side effects, supporting further progress to Phase 3 (Financial Times)
The intranasal BPL-003 treatment allowed most patients to be ready for discharge within 90 minutes after dosing—matching the standardized two-hour in-clinic psychiatric intervention model and potentially improving both access to treatment and cost-effectiveness (Financial Times)
The all-share acquisition of Beckley Psytech, valued at $390 million, gives ATAI full rights to BPL-003 and complementary assets, strategically consolidating ATAI’s pipeline and signaling strong investor confidence in its psychedelic therapy platform (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
ATAI Financial Performance
Revenues and expenses
ATAI Earnings Performance
Company profitability
ATAI News
AllArticlesVideos
atai Life Sciences marks milestone quarter with key clinical wins, Beckley merger plans
Proactive Investors4 weeks ago
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga2 months ago
atai eyes 2025 catalysts in psychedelic portfolio following Recognify trial update
Proactive Investors2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $986M as of September 13, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of September 13, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.